Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics Announces VYKAT(TM) XR Launch. Press Release Date 04-14-2025. First prescriptions delivered to individuals with PWS. REDWOOD CITY, Calif., April 14, 2025 ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics, Inc. has announced positive results from its clinical program for VYKAT™ XR (diazoxide choline) extended-release tablets, aimed at treating hyperphagia in individuals with ...

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, TD ...

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference Provided by GlobeNewswire Jun 25, 2025, 12:00:00 PM ...

Soleno Therapeutics Announces VYKAT(TM) XR Launch Provided by GlobeNewswire Apr 14, 2025 11:00am. REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ...

First prescriptions delivered to individuals with PWSREDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company ...

Soleno Therapeutics announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for hyperphagia in patients four years of age and older with Prader ...